What to Expect From Corbus Pharmaceuticals in 2018

What to Expect From Corbus Pharmaceuticals in 2018

For a brief few weeks in 2017, it looked like Corbus Pharmaceuticals (NASDAQ: CRBP) could be making another big play after a terrific performance in the previous year. The stock gained more than 20% year to date by late March.

And then it all fell apart. Corbus announced results from a phase 2 study of anabasum in treating cystic fibrosis. Although the company viewed the results as positive, most outside observers didn't. Corbus stock is now down nearly 20% in 2017 despite its promising start.

Will the new year bring a return to glory for the biotech or a continuation of 2017? Here's what to expect from Corbus Pharmaceuticals in 2018.

Continue reading

Source: Fool.com